Goldman Sachs’ David Solomon tells startups to reconsider going public
Goldman Sachs is one of the biggest investment banker “book runners” for IPOs -- where banks are paid many millions of ...
Goldman Sachs starts coverage on ResMed with "buy" rating
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
AMD faces analyst downgrades: could the MI350 chip series boost stock performance?
Analysts from Wolfe Research, Goldman Sachs, and HSBC downgrade AMD, citing weak AI chip demand and rising competition. Could ...
Citigroup faces £1 billion bill on London HQ overhaul with multi-level garden and mini villages to tempt staff back to the office
Citigroup’s lavish renovation of its 42-storey building in London’s Canary Wharf is expected to come with an eye-watering £1 ...
Advanced Micro Devices Stock Catches a Downgrade. Why This Analyst is Concerned.
Advanced Micro Devices may be losing its competitive edge, Wolfe Research analyst Chris Caso argued as he downgraded shares ...